oral influenza PB2 inhibitor CDI-42344 due to unexpectedly low influenza infection among study participants who were challenged with a H3N2 viral strain. This randomized, double-blind, ...

As international conflicts go, none did so little to disrupt the global order as the “whisky wars” that pitted Canada against Denmark for four decades. Flaring up in 1984, the unlikely spat ...

Undisciplined play cost Canada a shot at finishing atop the Group A standings at the world junior championship. Power-play goals by Cole Hutson, Danny Nelson and Cole Eiserman, plus an empty ...

Canada is set to take over the presidency of the G7 in 2025, leading a forum of seven of the world's most advanced economies at a time of political instability at home and around the world. Here's ...

Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of the oral influenza polymerase basic 2 (PB2) inhibitor, CC-42344, following unpredictable ...

With Canada facing a federal election and multiple challenges in 2025, the At Issue panel answers your political questions as the country heads into what is expected to be a challenging year.

Highly pathogenic avian influenza A(H5N1) viruses are circulating among wild birds and poultry in British Columbia, Canada. 1 These viruses are also recognized to cause illness in humans.

The study, which began in December 2023, is designed to assess the safety, tolerability, and antiviral activity of CC-42344, a broad-spectrum oral inhibitor targeting the influenza PB2 protein.

Meanwhile, Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of the oral influenza polymerase basic 2 (PB2) inhibitor, CC-4234. "Arcturus ...

The Canadian dollar rose to a near three-week high against its U.S. counterpart on Monday, as investors weighed the potential for Canada's economy to escape broad-based U.S. tariffs and a report ...

Here’s how Canada’s immigration rules are changing this year. Last October, the federal government announced that it would reduce the number of immigrants it brings in over the next three years, ...

Credit: Yurii_Yarema / Shutterstock. Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of the oral influenza polymerase basic 2 (PB2) inhibitor, ...